CELLULAR REJUVENATION : THE QUEST TO RESET AGE

💪 Dear Supermen and Superwomen,

What if our skin could literally "forget" its age ? The race for epigenetic reprogramming is accelerating. Turn Biotechnologies, a pioneer in cellular regeneration, has just acquired Harvard’s ARMMs technology. This therapeutic delivery system could overcome one of regenerative medicine’s last barriers: efficiently delivering treatments to targeted cells. With a clinical trial for skin rejuvenation scheduled for 2026, the future of longevity is becoming tangible.

SPOTLIGHT

Turn Biotechnologies, experts in epigenetic reprogramming, have taken a major step towards clinical applications by acquiring Harvard’s ARMMs technology. Designed to optimize cellular therapy delivery, this platform strengthens Turn Bio's eTurna system capabilities. The goal ? Better targeting tissues and enhancing treatment effectiveness against aging effects. Combining ARMMs with their existing approach, Turn Bio aims to treat skin, retina, liver, and immune cells. A clinical trial is planned for 2026 using the candidate TRN-001.

The Details :

• An innovative delivery solution : Harvard’s ARMMs technology utilizes human extracellular vesicles to transfer therapeutic agents between cells. This biomimetic approach promotes natural cellular communication, limiting side effects and increasing precision.

• Complementarity with eTurna : While Turn Bio's eTurna system uses lipid nanoparticles to target various tissues, ARMMs expands the therapeutic spectrum. Together, these technologies facilitate delivering complex therapeutic cocktails (proteins, RNA, gene editors) with high specificity.

• Avoiding immune responses : Unlike traditional viral vectors, ARMMs do not trigger immune responses, improving clinical tolerance—critical for future therapies requiring repeated dosing and long-term use.

• Promising preclinical results : Animal studies show effective delivery in several key organs: retina, lungs, liver, and nervous system. The platform is now ready for IND filing, paving the way for strategic partnerships.

• Clear clinical roadmap : Turn Bio plans to enter clinical trials for its skin rejuvenation treatment by 2026. Following a $300M partnership with HanAll Biopharma, the company solidifies its leadership role in regenerative medicine.

Key takeaway 😀

Integrating ARMMs technology into Turn Bio’s eTurna platform marks a strategic turning point in regenerative medicine. By overcoming one of the field’s main obstacles—efficient, targeted, non-toxic delivery of therapeutic agents—Turn Bio gains a rare technological advantage. This convergence opens the path to repeatable, highly specific epigenetic treatments applicable to numerous human tissues.

For investors, researchers, and clinicians, cellular reprogramming is transitioning from concept to clinical reality. Therapeutic rejuvenation is no longer a distant promise but a developing platform.

HYPE OR FACT ?

💭 “Viral vectors are the only reliable option for therapeutic gene delivery.”

❌ Hype

While effective, viral vectors can induce undesirable immune responses and pose safety risks. Non-viral alternatives such as extracellular vesicles (e.g., ARMMs) or lipid nanoparticles (e.g., eTurna) are emerging as viable, safer, and repeatable solutions.

✅ Source: Nature Reviews Drug Discovery (2023)

LONGEVITY WISDOM

UpperLongevity – Your daily dose of vitality! (Monday to Friday)

✨ Science Monday : A recent scientific discovery on longevity
🚀 Innovation Tuesday : Promising technological advancements extending life expectancy
🍏 Vitality Wednesday : Scientifically validated habits for a longer life
🧐 Myth-busting Thursday : Debunking common longevity myths
🎬 Inspiration Friday : An informative and inspiring longevity video

Don’t leave your healthy future to chance. Join our community of conscious, informed, and committed longevity seekers.

🔗 Click here to subscribe →